Physician profile
Eric Lovato
NPI 1194763342
$16,013.05
in general payments reported to CMS, 2019-2025
35 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,590 · 2022: $4,464 · 2023: $3,777 · 2024: $3,212 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,160 · Honoraria: $500 · Education: $284 · Travel and Lodging: $15.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,159.56 |
| Honoraria | $500.00 |
| Education | $284.17 |
| Travel and Lodging | $15.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,079.81 | 2021-2025 | Ilumya, Winlevi, Blu-U |
| Abbvie INC. | $1,943.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,144.12 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $994.20 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $861.66 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $852.18 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Genzyme Corporation | $808.17 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $805.72 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $694.30 | 2022-2024 | Sotyktu |
| Ucb, INC. | $680.84 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $649.65 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $581.47 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $541.94 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $348.74 | 2021-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $250.82 | 2024 | Daxxify |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $247.12 | 2024-2025 | |
| Journey Medical Corporation | $239.79 | 2021-2025 | |
| Incyte Corporation | $195.97 | 2021-2025 | Opzelura |
| Organon LLC | $189.48 | 2025 | Vtama |
| Epi Health, LLC | $174.06 | 2021-2022 | |
| Pfizer INC. | $94.98 | 2023-2025 | |
| Merz North America, INC. | $90.20 | 2024 | |
| Dermavant Sciences, INC. | $89.18 | 2023-2024 | Vtama |
| Almirall LLC | $79.97 | 2021-2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.76 | 2021-2025 | Duobrii, Siliq, Cabtreo |
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| Botanix Sb INC | $51.98 | 2025 | Sofdra |
| Medimetriks Pharmaceuticals, INC. | $42.80 | 2023 | |
| Vyne Pharmaceuticals INC. | $33.21 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.73 | 2024 | Fraxel, Clear & Brilliant |
| Krystal Biotech INC | $24.44 | 2024 | Vyjuvek |
| Biofrontera INC. | $23.22 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.24 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.81 | 2025 | Ycanth |
| Sebela Pharmaceuticals INC. | $15.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lovato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.